

# James Signorovitch

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4343439/publications.pdf>

Version: 2024-02-01

102  
papers

2,804  
citations

257450

24  
h-index

189892

50  
g-index

102  
all docs

102  
docs citations

102  
times ranked

4938  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Combined Prospective and Retrospective Comparison of Long-Term Functional Outcomes Suggests Delayed Loss of Ambulation and Pulmonary Decline with Long-Term Eteplirsen Treatment. <i>Journal of Neuromuscular Diseases</i> , 2022, 9, 39-52.	2.6	24
2	Overall survival in the real-world and clinical trials: a case study validating external controls in advanced melanoma. <i>Future Oncology</i> , 2022, 18, 1321-1331.	2.4	2
3	Real-world and natural history data for drug evaluation in Duchenne muscular dystrophy: suitability of the North Star Ambulatory Assessment for comparisons with external controls. <i>Neuromuscular Disorders</i> , 2022, 32, 271-283.	0.6	13
4	Incidence of acute otitis media in children in the United States before and after the introduction of 7- and 13-valent pneumococcal conjugate vaccines during 1998–2018. <i>BMC Infectious Diseases</i> , 2022, 22, 294.	2.9	19
5	Proposed Cardiac End Points for Clinical Trials in Immunoglobulin Light Chain Amyloidosis: Report From the Amyloidosis Forum Cardiac Working Group. <i>Circulation: Heart Failure</i> , 2022, 15, CIRCHEARTFAILURE121009038.	3.9	6
6	The Economic Burden of Recurrence in Triple-Negative Breast Cancer Among Working Age Patients in the United States. <i>Advances in Therapy</i> , 2022, 39, 943-958.	2.9	4
7	Carbon footprint and associated costs of asthma exacerbation care among UK adults. <i>Journal of Medical Economics</i> , 2022, 25, 524-531.	2.1	10
8	Comprehensive genomic profiling in advanced/metastatic colorectal cancer: number needed to test and budget impact of expanded first line use. <i>Journal of Medical Economics</i> , 2022, 25, 817-825.	2.1	2
9	Impact of choice of inhalers for asthma care on global carbon footprint and societal costs: a long-term economic evaluation. <i>Journal of Medical Economics</i> , 2022, 25, 940-953.	2.1	2
10	Variation in recurrence rate and overall survival (OS) outcomes by disease stage and incremental impact of time to recurrence on OS in localized renal cell carcinoma (RCC).. <i>Journal of Clinical Oncology</i> , 2022, 40, 4543-4543.	1.6	1
11	Real-world treatment patterns in von Hippel-Lindau (VHL) disease-associated renal cell carcinoma (RCC): Costs of tumor reduction procedures and their complications.. <i>Journal of Clinical Oncology</i> , 2022, 40, 4539-4539.	1.6	0
12	Long-term treatment effects of inotersen on health-related quality of life in patients with hereditary ATTR amyloidosis with polyneuropathy: Analysis of the open-label extension of the NEUROATTR trial. <i>Muscle and Nerve</i> , 2022, 66, 438-446.	2.2	3
13	Factors associated with increased health-related quality of life benefits in hereditary transthyretin amyloidosis polyneuropathy patients treated with inotersen. <i>Muscle and Nerve</i> , 2022, 66, 319-328.	2.2	0
14	Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. <i>JACC: Heart Failure</i> , 2021, 9, 65-73.	4.1	93
15	Risk of Nephrolithiasis and Nephrocalcinosis in Patients with Chronic Hypoparathyroidism: A Retrospective Cohort Study. <i>Advances in Therapy</i> , 2021, 38, 1946-1957.	2.9	19
16	Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy.. <i>Journal of Clinical Oncology</i> , 2021, 39, 4581-4581.	1.6	6
17	Comprehensive genomic profiling in advanced/metastatic colorectal cancer: Number needed to test and budget impact of expanded first-line use.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18834-e18834.	1.6	1
18	Steroid switching in dystrophinopathy treatment: a chart review of patient characteristics and clinical outcomes. <i>Journal of Comparative Effectiveness Research</i> , 2021, 10, 1065-1078.	1.4	3

#	ARTICLE	IF	CITATIONS
19	863. Pre-Exposure Prophylaxis (PrEP) Prescriptions among Individuals at High Risk for HIV in the United States, 2012-2018. <i>Open Forum Infectious Diseases</i> , 2021, 8, S523-S523.	0.9	0
20	Real-world treatment patterns and clinical outcomes for inpatients with COVID-19 in the US from September 2020 to February 2021. <i>PLoS ONE</i> , 2021, 16, e0261707.	2.5	5
21	Impact of Teduglutide on Quality of Life Among Patients With Short Bowel Syndrome and Intestinal Failure. <i>Journal of Parenteral and Enteral Nutrition</i> , 2020, 44, 119-128.	2.6	38
22	Deflazacort vs prednisone treatment for Duchenne muscular dystrophy: A meta-analysis of disease progression rates in recent multicenter clinical trials. <i>Muscle and Nerve</i> , 2020, 61, 26-35.	2.2	40
23	Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failure—DANISH-MRI. <i>American Heart Journal</i> , 2020, 221, 165-176.	2.7	35
24	The Amyloidosis Forum: a public private partnership to advance drug development in AL amyloidosis. <i>Orphanet Journal of Rare Diseases</i> , 2020, 15, 268.	2.7	9
25	Cost-effectiveness of olaparib as a maintenance treatment for women with newly diagnosed advanced ovarian cancer and BRCA1/2 mutations in the United States. <i>Gynecologic Oncology</i> , 2020, 159, 491-497.	1.4	16
26	Cost-effectiveness of pembrolizumab with axitinib as first-line treatment for advanced renal cell carcinoma. <i>Current Medical Research and Opinion</i> , 2020, 36, 1507-1517.	1.9	11
27	Letter to the Editor Regarding “Comparing Efficacy, Safety, and Preinfusion Period of Axicabtagene Ciloleucel versus Tisagenlecleucel in Relapsed/Refractory Large B Cell Lymphoma”. <i>Biology of Blood and Marrow Transplantation</i> , 2020, 26, e333-e334.	2.0	9
28	A Critical Appraisal and Recommendations for Cost-Effectiveness Studies of Poly(ADP-Ribose) Polymerase Inhibitors in Advanced Ovarian Cancer. <i>Pharmacoeconomics</i> , 2020, 38, 1201-1218.	3.3	5
29	An Economic Evaluation of Pembrolizumab Versus Other Adjuvant Treatment Strategies for Resected High-Risk Stage III Melanoma in the USA. <i>Clinical Drug Investigation</i> , 2020, 40, 629-643.	2.2	13
30	A Review of Two Regulatory Approved Anti-CD19 CAR T-Cell Therapies in Diffuse Large B-Cell Lymphoma: Why Are Indirect Treatment Comparisons Not Feasible?. <i>Advances in Therapy</i> , 2020, 37, 3040-3058.	2.9	34
31	Causal inference and adjustment for reference-arm risk in indirect treatment comparison meta-analysis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 737-750.	1.4	3
32	Prognostic factors for changes in the timed 4-stair climb in patients with Duchenne muscular dystrophy, and implications for measuring drug efficacy: A multi-institutional collaboration. <i>PLoS ONE</i> , 2020, 15, e0232870.	2.5	23
33	Suitability of external controls for drug evaluation in Duchenne muscular dystrophy. <i>Neurology</i> , 2020, 95, e1381-e1391.	1.1	27
34	Comparative safety and efficacy of ozanimod versus fingolimod for relapsing multiple sclerosis. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 275-285.	1.4	30
35	Real-world outcomes of long-term prednisone and deflazacort use in patients with Duchenne muscular dystrophy: experience at a single, large care center. <i>Journal of Comparative Effectiveness Research</i> , 2020, 9, 177-189.	1.4	28
36	PIK3CA mutation status and progression-free survival in advanced hormone receptor positive (HR+)/human endocrine receptor negative (HER2-) metastatic breast cancer (mBC): A meta-analysis of published clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 1069-1069.	1.6	3

#	ARTICLE	IF	CITATIONS
37	Cost-effectiveness of pembrolizumab in combination with axitinib as first-line treatment for advanced renal cell carcinoma.. Journal of Clinical Oncology, 2020, 38, 716-716.	1.6	2
38	The statistical performance of matching-adjusted indirect comparisons: Estimating treatment effects with aggregate external control data. Annals of Applied Statistics, 2020, 14, .	1.1	8
39	1480. Incidence of Non-Invasive Pneumococcal Pneumonia in Children in the United States before and after Introduction Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018. Open Forum Infectious Diseases, 2020, 7, S741-S742.	0.9	3
40	1479. Incidence of Acute Otitis Media in Children in the United States before and after the introduction of Pneumococcal Conjugate Vaccines (PCV7 and PCV13) during 1998-2018. Open Forum Infectious Diseases, 2020, 7, S740-S741.	0.9	3
41	Validation of an ambient measurement system (AMS) for physical activities in a paediatric population. Journal of Medical Engineering and Technology, 2019, 43, 182-189.	1.4	1
42	Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit. JACC: Heart Failure, 2019, 7, 717-724.	4.1	29
43	Real-World Effectiveness and Tolerability of Pazopanib as First Targeted Therapy in Metastatic Renal Cell Carcinoma: A Retrospective Chart Review in Latin America. Advances in Therapy, 2019, 36, 3446-3457.	2.9	1
44	Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma. Clinical Therapeutics, 2019, 41, 2357-2379.e1.	2.5	10
45	Categorising trajectories and individual item changes of the North Star Ambulatory Assessment in patients with Duchenne muscular dystrophy. PLoS ONE, 2019, 14, e0221097.	2.5	57
46	Real-world durability of relapse rate reduction in patients with multiple sclerosis receiving fingolimod for up to 3 years: a retrospective US claims database analysis. Journal of the Neurological Sciences, 2019, 398, 163-170.	0.6	4
47	Cost-effectiveness of pembrolizumab for the adjuvant treatment of resected high-risk stage III melanoma in the United States. Journal of Medical Economics, 2019, 22, 981-993.	2.1	20
48	Right Ventricular Dysfunction and the Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure. Circulation: Arrhythmia and Electrophysiology, 2019, 12, e007022.	4.8	19
49	Comparative efficacy of first-line ceritinib and crizotinib in advanced or metastatic anaplastic lymphoma kinase-positive non-small cell lung cancer: an adjusted indirect comparison with external controls. Current Medical Research and Opinion, 2019, 35, 105-111.	1.9	14
50	Budget impact analysis of comprehensive genomic profiling in patients with advanced non-small cell lung cancer. Journal of Medical Economics, 2019, 22, 140-150.	2.1	17
51	Real-World Clinical Burden of Sickle Cell Disease in the US Community-Practice Setting: A Single-Center Experience from the Foundation for Sickle Cell Disease Research. Blood, 2019, 134, 5856-5856.	1.4	4
52	MON-526 Risk of Cardiovascular (CV) Conditions in Patients with Chronic Hypoparathyroidism (HypoPT). Journal of the Endocrine Society, 2019, 3, .	0.2	0
53	Eteplirsen Delays Time to Loss of Ambulation in Patients With Duchenne Muscular Dystrophy Compared With Patients Receiving Standard of Care. Neuropediatrics, 2019, 50, .	0.6	0
54	Real-world persistence with fingolimod for the treatment of multiple sclerosis: A systematic review and meta-analysis. Journal of the Neurological Sciences, 2018, 388, 168-174.	0.6	10

#	ARTICLE	IF	CITATIONS
55	Real-world utilization of molecular diagnostic testing and matched drug therapies in the treatment of metastatic cancers. <i>Journal of Medical Economics</i> , 2018, 21, 543-552.	2.1	10
56	Estimated Cost of Anticancer Therapy Directed by Comprehensive Genomic Profiling in a Single-Center Study. <i>JCO Precision Oncology</i> , 2018, 2, 1-11.	3.0	17
57	Genotype and Lifetime Burden of Disease in Hypertrophic Cardiomyopathy. <i>Circulation</i> , 2018, 138, 1387-1398.	1.6	468
58	Response by Elming et al to Letter Regarding Article, "Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure". <i>Circulation</i> , 2018, 137, 2190-2190.	1.6	0
59	Comparative Efficacy of Treatments for Previously Treated Advanced or Metastatic Non-Small-Cell Lung Cancer: A Network Meta-Analysis. <i>Advances in Therapy</i> , 2018, 35, 1035-1048.	2.9	5
60	Epilepsy treatment patterns among patients with tuberous sclerosis complex. <i>Journal of the Neurological Sciences</i> , 2018, 391, 104-108.	0.6	19
61	Is time to progression associated with post-progression survival in previously treated metastatic non-small cell lung cancer with BRAF V600E mutation? A secondary analysis of phase II clinical trial data. <i>BMJ Open</i> , 2018, 8, e021642.	1.9	4
62	Consensus Grading of Cytokine Release Syndrome (CRS) in Adult Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r DLBCL) Treated with Tisagenlecleucel on the JULIET Study. <i>Blood</i> , 2018, 132, 4190-4190.	1.4	7
63	Grading of Neurotoxicity in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (r/r) Tj ETQq1 1 0.784314 rgBT /Over 1.4	1.4	7
64	Comparative effectiveness of nab-paclitaxel plus gemcitabine versus FOLFIRINOX in metastatic pancreatic cancer: A nationwide chart review in the United States.. <i>Journal of Clinical Oncology</i> , 2018, 36, 376-376.	1.6	6
65	Can Matching-Adjusted Indirect Comparison Methods Mitigate Placebo Response Differences Among Patient Populations in Adjunctive Trials of Brivaracetam and Levetiracetam?. <i>CNS Drugs</i> , 2017, 31, 899-910.	5.9	5
66	Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. <i>Circulation</i> , 2017, 136, 1772-1780.	1.6	134
67	Estimated cost of anticancer therapy directed by comprehensive genomic profiling (CGP) in a single-center study.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6605-6605.	1.6	5
68	Indirect Comparisons: A Brief History and a Practical Look Forward. , 2017, , 265-276.		0
69	Comprehensive genomic profiling (CGP) versus conventional molecular diagnostic testing of patients with advanced non-small cell lung cancer (NSCLC): Overall survival (OS) and cost in a U.S. health plan population.. <i>Journal of Clinical Oncology</i> , 2017, 35, 6599-6599.	1.6	1
70	Economic impact of expanded use of biologic therapy for the treatment of rheumatoid arthritis and Crohn's disease in Argentina, Brazil, Colombia, and Mexico. <i>Journal of Medical Economics</i> , 2016, 19, 1187-1199.	2.1	7
71	Association between time to progression and subsequent survival in ceritinib-treated patients with advanced ALK-positive non-small-cell lung cancer. <i>Current Medical Research and Opinion</i> , 2016, 32, 1911-1918.	1.9	3
72	Economic Evaluation of Timely Versus Delayed Use of Tumor Necrosis Factor Inhibitors for Treatment of Psoriatic Arthritis in the US. <i>Rheumatology and Therapy</i> , 2016, 3, 305-322.	2.3	4

#	ARTICLE	IF	CITATIONS
73	Comparative Efficacy of Ceritinib and Crizotinib as Initial ALK “Targeted Therapies in Previously Treated Advanced NSCLC: An Adjusted Comparison with External Controls. <i>Journal of Thoracic Oncology</i> , 2016, 11, 1550-1557.	1.1	39
74	Daclatasvir + asunaprevir versus sofosbuvir/ledipasvir for hepatitis C genotype 1 in Japanese patients: an indirect comparison. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 273-279.	1.4	3
75	Relationship between brain volume loss and cognitive outcomes among patients with multiple sclerosis: a systematic literature review. <i>Neurological Sciences</i> , 2016, 37, 165-179.	1.9	57
76	Burden of illness among patients with fragile X syndrome (FXS): a Medicaid perspective. <i>Current Medical Research and Opinion</i> , 2016, 32, 405-416.	1.9	14
77	Daclatasvir and Sofosbuvir Versus Sofosbuvir and Ribavirin in Patients with Chronic Hepatitis C Coinfected with HIV: A Matching-adjusted Indirect Comparison. <i>Clinical Therapeutics</i> , 2016, 38, 404-412.	2.5	13
78	Daclatasvir + sofosbuvir versus standard of care for hepatitis C genotype 3: a matching-adjusted indirect comparison. <i>Journal of Comparative Effectiveness Research</i> , 2016, 5, 129-139.	1.4	6
79	Individualized Prediction of Changes in 6-Minute Walk Distance for Patients with Duchenne Muscular Dystrophy. <i>PLoS ONE</i> , 2016, 11, e0164684.	2.5	51
80	Developing a Risk Score to Guide Individualized Treatment Selection in Attention Deficit/Hyperactivity Disorder. <i>Value in Health</i> , 2015, 18, 824-831.	0.3	7
81	The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis. <i>Journal of the Neurological Sciences</i> , 2015, 357, 8-18.	0.6	61
82	Health resource use and costs of vilazodone and other selective serotonin re-uptake inhibitors in treating major depressive disorder. <i>Journal of Medical Economics</i> , 2015, 18, 919-929.	2.1	2
83	Effect of Adherence and Insulin Delivery System on Clinical and Economic Outcomes among Patients with Type 2 Diabetes Initiating Insulin Treatment. <i>Value in Health</i> , 2015, 18, 198-205.	0.3	32
84	Real-world medication persistence with single versus multiple tablet regimens for HIV-1 treatment. <i>Journal of the International AIDS Society</i> , 2014, 17, 19537.	3.0	16
85	Comparative Effectiveness of Second-Line Targeted Therapies for Metastatic Renal Cell Carcinoma: A Systematic Review and Meta-Analysis of Real-World Observational Studies. <i>PLoS ONE</i> , 2014, 9, e114264.	2.5	35
86	Pulmonary Medication Adherence and Health-care Use in Cystic Fibrosis. <i>Chest</i> , 2014, 146, 142-151.	0.8	191
87	Major molecular response during the first year of dasatinib, imatinib or nilotinib treatment for newly diagnosed chronic myeloid leukemia: A network meta-analysis. <i>Cancer Treatment Reviews</i> , 2014, 40, 285-292.	7.7	16
88	Everolimus and sunitinib for advanced pancreatic neuroendocrine tumors: a matching-adjusted indirect comparison. <i>Experimental Hematology and Oncology</i> , 2013, 2, 32.	5.0	32
89	Comparative effectiveness research using matching-adjusted indirect comparison: an application to treatment with guanfacine extended release or atomoxetine in children with attention-deficit/hyperactivity disorder and comorbid oppositional defiant disorder. <i>Pharmacoepidemiology and Drug Safety</i> , 2012, 21, 130-137.	1.9	41
90	Overall survival with everolimus, sunitinib, and placebo for advanced pancreatic neuroendocrine tumors: A matching-adjusted indirect comparison of randomized trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 237-237.	1.6	2

#	ARTICLE	IF	CITATIONS
91	Remission of major depressive disorder without adverse events: a comparison of escitalopram versus serotonin norepinephrine reuptake inhibitors. <i>Current Medical Research and Opinion</i> , 2011, 27, 1089-1096.	1.9	9
92	Validation of the FACIT-fatigue subscale, selected items from FACT-thrombocytopenia, and the SF-36v2 in patients with chronic immune thrombocytopenia. <i>Quality of Life Research</i> , 2011, 20, 1737-1744.	3.1	42
93	Cardiovascular and Economic Outcomes After Initiation of Atorvastatin versus Simvastatin in an Employed Population Stratified by Cardiovascular Risk. <i>American Journal of Therapeutics</i> , 2011, 18, 436-448.	0.9	4
94	Increased Olanzapine Discontinuation and Health Care Resource Utilization Following a Medicaid Policy Change. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 787-794.	2.2	6
95	Abstract P90: Cardiovascular and Economic Outcomes Following Initiation of Atorvastatin versus Simvastatin in an Employed Population Stratified by Cardiovascular Risk. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2011, 4, .	2.2	0
96	Incomparable Effectivenessâ€”Apples to Apples?â€”Replyâ€”l. <i>Mayo Clinic Proceedings</i> , 2010, 85, 764-767.	3.0	0
97	Cardiovascular and Economic Outcomes After Initiation of Lipid-Lowering Therapy With Atorvastatin vs Simvastatin in an Employed Population. <i>Mayo Clinic Proceedings</i> , 2009, 84, 1065-1072.	3.0	20
98	Response to The J-Point Revisited. <i>Hypertension</i> , 2008, 51, .	2.7	0
99	Effect of Antecedent Hypertension and Follow-Up Blood Pressure on Outcomes After High-Risk Myocardial Infarction. <i>Hypertension</i> , 2008, 51, 48-54.	2.7	69
100	Intrinsic Circadian Clock of the Mammalian Retina: Importance for Retinal Processing of Visual Information. <i>Cell</i> , 2007, 130, 730-741.	28.9	389
101	Correcting for ascertainment biases when analyzing SNP data: applications to the estimation of linkage disequilibrium. <i>Theoretical Population Biology</i> , 2003, 63, 245-255.	1.1	134
102	Linkage Disequilibrium and Inference of Ancestral Recombination in 538 Single-Nucleotide Polymorphism Clusters across the Human Genome. <i>American Journal of Human Genetics</i> , 2003, 73, 285-300.	6.2	76